文献速递核素与放射性配体治疗肿瘤 PET/CT神经核医学

SSTR导向的肽受体放射性核素治疗用于复发脑膜瘤:安全性、疗效及预后因素分析

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-02

单中心研究纳入32例复发脑膜瘤患者,接受[177Lu]Lu-DOTATOC/-TATE的PRRT治疗,回顾性评估安全性和疗效。PRRT仅见轻度血液学和肾脏毒性,多数不良事件为低级别(87%)。WHO III级患者的OS(10个月)和PFS(4.5个月)显著短于I级和II级,多变量分析中仅WHO分级是疾病进展的独立预测因子。

要点

  • PRRT治疗复发脑膜瘤仅见轻度血液学和肾脏毒性,87%不良事件为低级别。
  • WHO III级患者OS为10个月,显著短于I级(未达到,HR 4.77)和II级(47个月,HR 4.05)。
  • WHO III级患者PFS为4.5个月,显著短于I级(17个月,HR 6.47)和II级(17个月,HR 2.71)。

核心结论

  • PRRT是一种安全的治疗选择,似乎在复发脑膜瘤患者中具有有利效应。
  • WHO肿瘤分级是PFS和OS的最强预测因子,而基线PET参数似乎无预后价值。

研究设计与样本

  • 单中心研究纳入32例复发脑膜瘤患者,接受[177Lu]Lu-DOTATOC/-TATE的PRRT治疗。
  • 治疗前评估包括[68Ga]Ga-DOTATOC PET显像、常规血液学和血清生化分析。
  • 回顾性评估PFS、OS和治疗相关毒性,采用Kaplan-Meier生存分析和Cox回归模型。

主要发现

  • PRRT仅见轻度血液学和肾脏毒性,多数不良事件为低级别(87%)。
  • WHO III级患者OS为10个月,显著短于I级(未达到,HR 4.77,p<0.01)和II级(47个月,HR 4.05,p=0.01)。
  • WHO III级患者PFS为4.5个月,显著短于I级(17个月,HR 6.47,p<0.001)和II级(17个月,HR 2.71,p=0.02)。
  • 多变量分析中仅较高的WHO分级是疾病进展的独立预测因子,基线PET和实验室参数未见一致关联。
  • 随访PET中SSTR阳性肿瘤体积增加与更短PFS相关(HR 1.02,p=0.02)。

关键数值与推荐

  • WHO III级较I级:OS HR 4.77(p<0.01),PFS HR 6.47(p<0.001)。
  • WHO III级较II级:OS HR 4.05(p=0.01),PFS HR 2.71(p=0.02)。
  • 随访PET中SSTR阳性肿瘤体积增加与更短PFS相关,HR 1.02(p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluates safety and efficacy of peptide receptor radionuclide therapy (PRRT) as a stand-alone treatment for recurrent meningiomas and investigates the prognostic value of laboratory markers and quantitative PET parameters. METHODS: The single-center study includes 32 patients with recurrent meningioma, who underwent PRRT with [177Lu]Lu-DOTATOC/-TATE. Pre-treatment assessments comprised [68 Ga]Ga-DOTATOC PET imaging, routine hematology and serum chemistry analysis. Outcomes including progression-free survival (PFS), overall survival (OS), and treatment related toxicity, were retrospectively evaluated using Kaplan-Meier survival analysis and Cox regression models. RESULTS: PRRT showed only mild hematological and renal toxicity, with most adverse events being low-grade (87%). OS was significantly shorter in patients with WHO grade III meningiomas (10 months) compared to grade I (not reached, HR 4.77, p < 0.01) and grade II (47 months, HR 4.05, p = 0.01). Similarly, PFS was shorter in patients with WHO grade III meningiomas (4.5 months) compared to grade I (17 months, HR 6.47, p < 0.001) and grade II (17 months, HR 2.71, p = 0.02). In multivariable analysis, only higher WHO grade was an independent predictor of disease progression, while baseline PET and laboratory parameters showed no consistent association. Furthermore, increase of SSTR-positive tumor volume in follow-up PET was associated with shorter PFS (HR 1.02, p = 0.02). CONCLUSION: PRRT is a safe treatment option and appears to have a favourable effect in patients with recurrent meningiomas. WHO tumor grade is the strongest predictor of PFS and OS, while baseline PET parameters appear to have no prognostic value.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hasenauer N, Müller M, Hänscheid H, et al. SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40455253. doi:10.1007/s00259-025-07336-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。